LSTA Lisata Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: LSTA
Price (delayed)
$2.18
Market cap
$19.09M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.23
Enterprise value
$2.25M
Relative Growth:
Rel. Growth:
9
Relative Strength:
Rel. Strength:
23
Relative Valuation:
Rel. Valuation:
7
Relative Profitability:
Rel. Profitability:
31
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely
Highlights
The EPS has grown by 13% YoY and by 3% from the previous quarter
The net income has grown by 10% YoY
LSTA's equity is down by 45% YoY and by 17% from the previous quarter
Lisata Therapeutics's quick ratio has decreased by 39% YoY and by 25% from the previous quarter
Key stats
What are the main financial stats of LSTA
Market
Valuations
Earnings
Shares outstanding
8.76M
Market cap
$19.09M
Enterprise value
$2.25M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.89
Price to sales (P/S)
17.53
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.11
Revenue
$1.07M
Gross profit
$1.07M
Operating income
-$21M
Net income
-$18.92M
EBIT
-$19.89M
EBITDA
-$19.72M
Free cash flow
-$16.43M
Per share
Balance sheet
Liquidity
EPS
-$2.23
EPS diluted
-$2.23
Free cash flow per share
-$1.91
Book value per share
$2.45
Revenue per share
$0.12
TBVPS
$2.91
Total assets
$25.16M
Total liabilities
$4.39M
Debt
$0
Equity
$21.03M
Working capital
$20.57M
Debt to equity
0
Current ratio
5.77
Quick ratio
5.21
Net debt/EBITDA
0.85
Margins
Efficiency
Dividend
EBITDA margin
-1,842.5%
Gross margin
100%
Net margin
-1,768.5%
Operating margin
-1,962.6%
Return on assets
-59.4%
Return on equity
-69%
Return on invested capital
-224.6%
Return on capital employed
-95.4%
Return on sales
-1,858.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LSTA stock price
How has the Lisata Therapeutics stock price performed over time
Intraday
-6.84%
1 week
-18.35%
1 month
-13.15%
1 year
-25.34%
YTD
-26.85%
QTD
-16.79%
Financial performance
How have Lisata Therapeutics's revenue and profit performed over time
Revenue
$1.07M
Gross profit
$1.07M
Operating income
-$21M
Net income
-$18.92M
Gross margin
100%
Net margin
-1,768.5%
LSTA's operating income is up by 13% year-on-year and by 3% since the previous quarter
The net income has grown by 10% YoY
The operating margin has grown by 9% from the previous quarter
The net margin has grown by 8% from the previous quarter
Price vs fundamentals
How does LSTA's price correlate with its fundamentals
Growth
What is Lisata Therapeutics's growth rate over time
Valuation
What is Lisata Therapeutics stock price valuation
P/E
N/A
P/B
0.89
P/S
17.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.11
The EPS has grown by 13% YoY and by 3% from the previous quarter
LSTA's price to book (P/B) is 60% higher than its 5-year quarterly average of 0.6 and 7% higher than its last 4 quarters average of 0.9
LSTA's equity is down by 45% YoY and by 17% from the previous quarter
The revenue has grown by 7% since the previous quarter
Efficiency
How efficient is Lisata Therapeutics business performance
The return on invested capital has dropped by 95% year-on-year and by 14% since the previous quarter
LSTA's ROE is down by 49% YoY and by 13% from the previous quarter
Lisata Therapeutics's return on assets has decreased by 43% YoY and by 11% QoQ
The ROS has grown by 8% from the previous quarter
Dividends
What is LSTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LSTA.
Financial health
How did Lisata Therapeutics financials performed over time
The company's total assets fell by 41% YoY and by 13% QoQ
LSTA's current ratio is down by 39% YoY and by 23% QoQ
The debt is 100% less than the equity
LSTA's equity is down by 45% YoY and by 17% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.